Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood - Liu, Z.; Martin, J.; Orme, L.; Seddon, B.; Desai, J.; Nicholls, W.; Thomson, D.; Porter, D.; McCowage, G.; Underhill, C.; Cranswick, N.; Michael, M.; et al. (Cancer chemotherapy and pharmacology, 2018)
Keywords: Adolescent; Adolescents; Adult; Age Factors; Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - pharmacokinetics; Antibiotics, Antineoplastic - therapeutic use; Bone Neoplasms - drug therapy; Bone Neoplasms - metabolism; Cancer Research; Children; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - analogs & derivatives; Doxorubicin - pharmacokinetics; Doxorubicin - therapeutic use; Ewing's sarcoma; Ewings sarcoma; Female; Females; Gender; Hodgkin Disease - drug therapy; Hodgkin Disease - metabolism; Hodgkin's lymphoma; Humans; Lymphoma; Medicine; Medicine & Public Health; Models, Biological; Neoplasms - drug therapy; Neoplasms - metabolism; Oncology; Original Article; Osteosarcoma; Patients; Pharmacokinetics; Pharmacology/Toxicology; Pregnancy; Prospective Studies; Sarcoma, Ewing - drug therapy; Sarcoma, Ewing - metabolism; Sex Characteristics; Sex differences; Young Adult; Adolescent and young adult; Pharmacokinetics modelling; Ewing sarcoma; Osteosarcoma; Hodgkin’s lymphoma; Gender; Doxorubicin; Doxorubicinol